Presentation will highlight the development of functional 3D bioprinted co-cultured human hepatocyte spheroids for use as a liver tissue therapeutic
Vancouver, BC, Canada, November 3, 2021 - Aspect Biosystems, a biotechnology company pioneering the development of bioprinted cell therapies as medicines of the future, will present new data on its bioprinted liver tissues at the The Liver Meeting 2021, hosted by the American Association for the Study of Liver Diseases (AASLD), held virtually from November 12-15, 2021. This data highlights that the bioprinted liver tissues maintain viability and function for over 28 days in vivo.
“We are excited to share preclinical data showing that our bioprinted liver tissues maintain viability and function in mice, as demonstrated by stable circulating levels of human albumin and alpha-1 antitrypsin for extended periods in vivo,” said Dr. Sam Wadsworth, Chief Scientific Officer, Aspect Biosystems. “We believe bioprinted cell therapy shows immense promise for the treatment of a variety of acquired and chronic liver diseases, and this encouraging data represents an important step on our mission to develop curative therapies for these devastating diseases.”
- Presentation Title: Use of 3D bioprinted primary human hepatocytes and mesenchymal stem cells for the treatment of acute liver failure
- Presenter: Dr. Christopher Dickman, Lead Research Scientist at Aspect Biosystems
- Session Title: Late-breaking Abstract Posters
- Date: Available on-demand throughout the meeting
Learn more about Aspect’s bioprinted therapeutic programs at www.aspectbiosystems.com/programs
About the American Association for the Study of Liver Diseases (AASLD)
AASLD is the leading organization of scientists and health care professionals committed to preventing and curing liver disease. They foster research that leads to improved treatment options for millions of liver disease patients. They advance the science and practice of hepatology through educational conferences, training programs, professional publications, and partnerships with government agencies and sister societies.
The Liver Meeting, hosted by AASLD, brings together clinicians, associates, and scientists from around the world to exchange information on the latest research, discuss new developments in liver treatment and transplantation, and network with leading experts in the field of hepatology.
About Aspect Biosystems
Aspect Biosystems is a biotechnology company creating bioprinted therapeutics as medicines of the future. Aspect is applying its microfluidic 3D bioprinting technology internally to develop these advanced cell therapies and partnering with leading researchers and industry innovators worldwide to tackle the biggest challenges in regenerative medicine. Learn more at www.aspectbiosystems.com.